A new analysis has concluded that Rituximab ( MabThera, Rituxan ), a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura ( ITP ).
The study was published in Blood, the Journal of the American Society of Hematology ( ASH ).
Approximately 200,000 Americans suffer from immune thrombocytopenic purpura, a bleeding disorder in which the immune system destroys blood cells called platelets that are necessary for normal blood clotting, which can result in excessive bleeding and heavy bruising. Common treatment options for increasing platelet counts in the majority of patients with ITP include corticosteroid drug therapy, used to suppress a patients immune system in order to help bring platelet counts back to normal; splenectomy, the surgical removal of the spleen, to halt the destruction of antibody-coated platelets found in the organ; and newer thrombopoietin ( TPO )-mimetic agents to help stimulate platelet production. While these treatments are successful in many patients, all are associated with side effects: corticosteroids are associated with bone loss, cataracts, and other serious toxicity with long-term use; splenectomy can increase a patients risk of infection; and TPO-mimetic agents can result in blood clots, and their long-term response in patients is not well-studied. In addition to their reported side effects, some patients with immune thrombocytopenic purpura stop responding or have insufficient response to these therapies.
More than ten years ago, researchers identified Rituximab as an alternative treatment for patients with chronic immune thrombocytopenic purpura who have failed at least one other therapy. Rituximab specifically destroys B-cells, the cells responsible for producing antibodies that coat platelets and lead to their destruction, with low toxicity and decreased risk of infection compared to other treatments. Previous studies have shown that Rituximab treatment resulted in normalized platelet counts lasting longer than one year in some patients with chronic immune thrombocytopenic purpura. Despite these encouraging reports, long-term data were previously lacking, and the durability and long-term safety of this treatment were largely unknown.
In this follow-up study, Vivek L. Patels team at Weill Cornell Medical College in New York reviewed 18 published clinical trials assessing Rituximab treatment in children and adults with immune thrombocytopenic purpura and calculated initial and one-year response rates for 138 patients treated in 2000-2007 from seven clinical Centers in the United States and Europe. Seventy-two adults with ongoing response one year from first treatment and 66 children with partial or complete response of any duration were included in the long-term analysis. The researchers calculated five-year response rates of 26% for children and 21% for adults. The researchers also analyzed the relationship of other clinical variables in response to Rituximab and found no difference in projected five-year outcomes in children and adults who had undergone prior splenectomy versus those who had not. Age, gender, prior immune thrombocytopenic purpura duration, and response to other ITP treatment were also not predictive of duration of response.
The results from this study provide clinicians and patients with accurate and realistic expectations of the long-term effect of Rituximab and its potential to become a first-line treatment for immune thrombocytopenic purpura. The step is to try to augment the effect of Rituximab by combining it with Dexamethasone, a common steroid therapy for immune thrombocytopenic purpura, in order to determine its effect in conjunction with known treatment strategies. ( Xagena )
Source: American Society of Hematology, 2012